Search Clinical Trials in the European Union

Duration
11-15 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 306 trials

High Blood Pressure: Metyrapone for Adrenal Tumors

We are studying if adding Metyrapone helps patients with high blood pressure and adrenal tumors manage their condition better. This trial aims to improve blood pressure control in those with subclinical Cushing's syndrome.

Adrenal Incidentalomas and Mild Cushing’s Syndrome>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

X-ALD: Pramipexole for Leg Symptoms

We are investigating whether pramipexole can help reduce restless leg symptoms in women with X-linked Adrenoleukodystrophy. This study aims to improve their sleep and walking performance.

X-linked AdrenoleukodystrophyRestless Legs Syndrome3-6 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurology

Ulcerative Colitis: Comparing Risankizumab and Vedolizumab

We are studying whether risankizumab is more effective and safe than vedolizumab for adults with moderate to severe ulcerative colitis who have not yet received targeted treatments.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Chronic Heart Failure: Ferric Derisomaltose Treatment

We are studying whether ferric derisomaltose can improve heart health and reduce hospitalizations in people with iron deficiency and chronic heart failure. This trial compares it to no intravenous iron treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Heart Failure: Omecamtiv Mecarbil Study

We are testing a new medication for people with chronic heart failure and severely reduced heart function. The study aims to see if it can improve heart health outcomes compared to a placebo.

Heart Failure with Reduced Ejection Fraction>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Remdesivir for COVID-19 in Kidney Transplant Patients

We are studying whether a 10-day treatment with remdesivir can help kidney transplant recipients with mild or no COVID-19 symptoms avoid severe illness. The trial will also look at the safety and health outcomes of these patients.

COVID-196-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInfectious DiseasesNephrology

Systemic Lupus Erythematosus: CC-97540 CAR T Cell Therapy

We are studying a new CAR T cell therapy for people with active lupus who haven't responded to standard treatments. The goal is to see if it can improve symptoms and overall health.

Systemic Lupus ErythematosusLupus Nephritis>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyRheumatology

Severe Asthma: Verekitug (UPB-101) Study

We are studying the long-term safety and effects of verekitug in adults with severe asthma. This research aims to see how it helps manage asthma attacks and improve breathing.

Severe Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Microscopic Colitis: SAR444336 Treatment Study

We are investigating a new treatment, SAR444336, for adults with microscopic colitis in remission. The study aims to see if it can effectively manage symptoms without steroids and evaluate its safety.

Microscopic Colitis6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

Alzheimer's Disease: NPI-001 Study

We are testing a new oral medication, NPI-001, for people aged 50 to 85 with Mild Cognitive Impairment or mild dementia due to Alzheimer's. The study aims to assess its safety and effects on brain health and cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Multiple Myeloma: Comparing Treatment Approaches

We are studying two treatment plans for newly diagnosed multiple myeloma patients who cannot have a transplant. Our goal is to see which plan helps more patients reach a state of minimal disease.

Multiple MyelomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

ALS Treatment: EH-301 and N-Acetylcysteine with Riluzole

We are studying a new combination therapy for people with ALS to see if it can slow disease progression and improve muscle strength and quality of life. This trial compares the treatment to a placebo to evaluate its effectiveness.

Amyotrophic Lateral Sclerosis (ALS)1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Nucresiran for Transthyretin Amyloidosis with Cardiomyopathy

We are studying whether Nucresiran can help reduce serious heart-related events in patients with transthyretin amyloidosis. The trial compares its effects to a placebo to assess overall health improvements.

Transthyretin Amyloidosis with Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Plaque Psoriasis: Oral Piclidenoson Study

We are testing an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. The goal is to see if it can significantly improve skin symptoms compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Bladder Cancer: EMDA-MMC Treatment Study

We are evaluating a new treatment using electric current to deliver mitomycin C for high-grade non-muscle invasive bladder cancer. This study compares its effectiveness and safety to the standard BCG therapy.

Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Prostate Cancer: JSB462 and Lutetium Combination Study

We are studying a new treatment combining JSB462 with lutetium for adult men with advanced prostate cancer. The goal is to see how well this combination works and its safety compared to standard treatment.

Metastatic Castration-Resistant Prostate Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Type 2 Diabetes: RO7795081 Medication Study

We are comparing a new medication, RO7795081, with a placebo and semaglutide in people with type 2 diabetes. The study aims to see how well it controls blood sugar and affects body weight.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

Type 2 Diabetes: LY3457263 Treatment Study

We are testing a new medication, LY3457263, in people with type 2 diabetes who are not meeting their blood sugar goals on current treatments. The study will compare its effects to a placebo over 24 weeks.

Type 2 DiabetesEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Generalized Myasthenia Gravis: Descartes-08 Treatment

We are studying a new treatment called Descartes-08 for people with generalized myasthenia gravis. The trial aims to see if it helps improve daily activities and muscle strength compared to a placebo.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Diabetic Macular Edema: BI 1815368 Study

We are testing whether the oral medication BI 1815368 can improve vision in people with diabetic macular edema. The study will also look at the safety of this treatment over time.

Diabetic Macular Edema6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyOphthalmology